ArticleRespiratory research2014
Altered molecular specificity of surfactant phosphatidycholine synthesis in patients with acute respiratory distress syndrome.
Article in Respiratory research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362059 (A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- A randomized controlled trial of nebulized surfactant for the treatment of severe COVID-19 in adults (COVSurf trial).Scientific reports · 2023Trial
- Plasma Lipidomics Identify Pathways Linked to Acute Lung Injury in a Porcine One-Lung Ventilation Surgery Model.International journal of molecular sciences · 2026Article
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- Hypoxic Status in COPD and ARDS Patients: Impact on Lipid Signature.International journal of molecular sciences · 2025Article
- Exploring the Influence of Metabolic Changes in Fibrotic Lung Diseases.Pulmonary circulation · 2025Review
- Transfusion-Related Acute Lung Injury: from Mechanistic Insights to Therapeutic Strategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Metabolic Regulation in Acute Respiratory Distress Syndrome: Implications for Inflammation and Oxidative Stress.International journal of chronic obstructive pulmonary disease · 2025Review
- Article
- Particles in Exhaled Air (PExA): Clinical Uses and Future Implications.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Oxidative stress, redox status and surfactant metabolism in mechanically ventilated patients receiving different approaches to oxygen therapy (MecROX): An observational study protocol for mechanistic evaluation.NIHR open research · 2024Article
- Alveolar Hyperoxia and Exacerbation of Lung Injury in Critically Ill SARS-CoV-2 Pneumonia.Medical sciences (Basel, Switzerland) · 2023Review
- Pulmonary Surfactant in Adult ARDS: Current Perspectives and Future Directions.Diagnostics (Basel, Switzerland) · 2023Review
- Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.Critical care explorations · 2021Article
- Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.Respiratory research · 2021Article
- Understanding the Functional Properties of Lipid Heterogeneity in Pulmonary Surfactant Monolayers at the Atomistic Level.Frontiers in cell and developmental biology · 2020Article
- Lack of whey acidic protein (WAP) four-disulfide core domain protease inhibitor 2 (WFDC2) causes neonatal death from respiratory failure in mice.Disease models & mechanisms · 2019Article
- Reshaping Lipid Biochemistry by Pushing Barriers in Structural Lipidomics.Angewandte Chemie (International ed. in English) · 2019Review
- Insight into erythrocyte phospholipid molecular flux in healthy humans and in patients with acute respiratory distress syndrome.PloS one · 2019Article
- Metabolism of a synthetic compared with a natural therapeutic pulmonary surfactant in adult mice.Journal of lipid research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute respiratory distress syndrome (ARDS) is a life-threatening critical illness, characterised by qualitative and quantitative surfactant compositional changes associated with premature airway collapse, gas-exchange abnormalities and acute hypoxic respiratory failure. The underlying mechanisms for this dysregulation in surfactant metabolisms are not fully explored. Lack of therapeutic benefits from clinical trials, highlight the importance of detailed in-vivo analysis and characterisation of ARDS patients according to patterns of surfactant synthesis and metabolism.
methodsTen patients with moderate to severe ARDS were recruited. Most (90%) suffered from pneumonia. They had an infusion of methyl-D9-choline chloride and small volume bronchoalveolar lavage fluid (BALF) was obtained at 0,6,12,24,48,72 and 96 hours. Controls were healthy volunteers, who had BALF at 24 and 48 hours after methyl-D9-choline infusion. Compositional analysis and enrichment patterns of stable isotope labelling of surfactant phosphatidylcholine (PC) was determined by electrospray ionisation mass spectrometry.
resultsBALF of patients with ARDS consisted of diminished total PC and fractional PC16:0/16:0 concentrations compared to healthy controls. Compositional analysis revealed, reductions in fractional compositions of saturated PC species with elevated levels of longer acyl chain unsaturated PC species. Molecular specificity of newly synthesised PC fraction showed time course variation, with lower PC16:0/16:0 composition at earlier time points, but achieved near equilibrium with endogenous composition at 48 hours after methyl-D9-choline infusion. The enrichment of methyl-D9-choline into surfactant total PC is nearly doubled in patients, with considerable variation between individuals.
conclusionsThis study demonstrate significant alterations in composition and kinetics of surfactant PC extracted from ARDS patients. This novel approach may facilitate biochemical phenotyping of ARDS patients according to surfactant synthesis and metabolism, enabling individualised treatment approaches for the management of ARDS patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.